Inhibiting inflammation with milk oligosaccharides
A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.
1. A method of inhibiting inflammation in a subject, comprising administering to a subject a composition consisting essentially of an effective amount of a 2′-fucosyllactose, wherein the subject is suffering from irritable bowel syndrome (IBS).
2. The method of claim 1 , wherein the composition is free from fat and protein.
3. The method of claim 1 , wherein the 2′-fucosyllactose is synthesized chemically or produced by a microorganism.
4. The method of claim 1 , wherein secretion of one or more pro-inflammatory cytokines is reduced in the subject.
5. The method of claim 4 , wherein the one or more pro-inflammatory cytokines is selected from the group consisting of IL-1, IL-6, TNF-alpha, GM-CSF, IL-8, and IL-12.
6. The method of claim 5 , wherein the one or more pro-inflammatory cytokines is TNF-alpha.
7. The method of claim 1 , wherein secretion of MCP-1 is reduced in the subject.
8. The methods of claim 4 , wherein the secretion is in the intestinal mucosa.
9. The method of claim 1 , wherein pain is reduced in the subject.
10. The method of claim 1 , wherein the composition is an oral formulation.
11. The method of claim 1 , wherein the subject is a human IBS patient.
12. A method of treating irritable bowel syndrome (IBS), comprising administering to a subject suffering from IBS a composition consisting essentially of an effective amount of 2′-fucosyllactose.
13. The method of claim 12 , wherein the composition is free from fat and protein.
14. The method of claim 12 , wherein the 2′-fucosyllactose is synthesized chemically or produced by a microorganism.
15. The method of claim 12 , wherein secretion of one or more pro-inflammatory cytokines is reduced in the subject.
16. The method of claim 15 , wherein the one or more pro-inflammatory cytokines is selected from the group consisting of IL-1, IL-6, TNF-alpha, GM-CSF, IL-8, and IL-12.
17. The method of claim 16 , wherein the one or more pro-inflammatory cytokines is TNF-alpha.
18. The method of claim 12 , wherein secretion of MCP-1 is reduced in the subject.
19. The methods of claim 15 , wherein the secretion is in the intestinal mucosa.
20. The method of claim 12 , wherein pain is reduced in the subject.
21. The method of claim 12 , wherein the composition is an oral formulation.
22. The method of claim 12 , wherein the subject is a human IBS patient.